Clinical pharmacology of taxanes as radiosensitizers and the thiol- based radioprotectant amifostine

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although many anticancer agents have been evaluated as radiosensitizing agents in cancer patients, none has demonstrated unequivocal clinical efficacy. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to enhance tumor cell response to ionizing radiation in cell culture studies. The pharmacokinetics and pharmacodynamics of paclitaxel in cancer patients receiving other highly metabolized drugs have not been well described and will be a key consideration in the development of the drug as a radiosensitizing agent. In addition, drug interaction studies demonstrate that administration sequence of paclitaxel with other chemotherapeutic agents, including cisplatin, doxorubicin, and cyclophosphamide, likely will affect its radiosensitizing efficacy. Other drugs that may affect paclitaxel radiosensitizing efficacy include corticosteroids and anticonvulsants; these interactions are particularly important in patients with central nervous system tumors, as is the question of whether paclitaxel can penetrate the blood-brain barrier. Overall, paclitaxel pharmacokinetics appear to favor radiosensitization, and results from an ongoing series of randomized trials should help define the drug's role in this setting. In contrast, amifostine, a sulfhydryl-containing agent, is currently being evaluated as a radioprotectant for normal tissues in patients who are receiving radiation therapy. Recent clinical trials have focused on amifostine's ability to reduce platinum-induced nephrotoxicity, although the drug was originally developed as a radioprotectant. Phase I clinical trials suggest that amifostine may be administered in much lower doses for radioprotection than those required for protection from platinum-induced nephrotoxicity. Amifostine pharmacokinetics support this finding; elimination of the drug may be dose dependent with clearance saturated at high doses, leading to increased risk of toxicity with no added radioprotectant benefit. Large randomized trials evaluating both paclitaxel as a radiosensitizer and amifostine as a radioprotectant are needed to make any firm conclusions regarding efficacy of either drug in modulating cancer therapy.

Original languageEnglish (US)
Pages (from-to)66-76
Number of pages11
JournalSeminars in Radiation Oncology
Volume7
Issue number3 SUPPL. 2
StatePublished - 1997

Fingerprint

pharmacology
Amifostine
Taxoids
Clinical Pharmacology
Paclitaxel
Sulfhydryl Compounds
thiols
drugs
Pharmaceutical Preparations
Radiation-Sensitizing Agents
Pharmacokinetics
Platinum
cancer
dosage
Neoplasms
platinum
anticonvulsants
tumors
corticosteroids
Central Nervous System Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Clinical pharmacology of taxanes as radiosensitizers and the thiol- based radioprotectant amifostine. / Dorr, Robert T.

In: Seminars in Radiation Oncology, Vol. 7, No. 3 SUPPL. 2, 1997, p. 66-76.

Research output: Contribution to journalArticle

@article{8e15d1c695f34ad0a95e349ac847a038,
title = "Clinical pharmacology of taxanes as radiosensitizers and the thiol- based radioprotectant amifostine",
abstract = "Although many anticancer agents have been evaluated as radiosensitizing agents in cancer patients, none has demonstrated unequivocal clinical efficacy. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to enhance tumor cell response to ionizing radiation in cell culture studies. The pharmacokinetics and pharmacodynamics of paclitaxel in cancer patients receiving other highly metabolized drugs have not been well described and will be a key consideration in the development of the drug as a radiosensitizing agent. In addition, drug interaction studies demonstrate that administration sequence of paclitaxel with other chemotherapeutic agents, including cisplatin, doxorubicin, and cyclophosphamide, likely will affect its radiosensitizing efficacy. Other drugs that may affect paclitaxel radiosensitizing efficacy include corticosteroids and anticonvulsants; these interactions are particularly important in patients with central nervous system tumors, as is the question of whether paclitaxel can penetrate the blood-brain barrier. Overall, paclitaxel pharmacokinetics appear to favor radiosensitization, and results from an ongoing series of randomized trials should help define the drug's role in this setting. In contrast, amifostine, a sulfhydryl-containing agent, is currently being evaluated as a radioprotectant for normal tissues in patients who are receiving radiation therapy. Recent clinical trials have focused on amifostine's ability to reduce platinum-induced nephrotoxicity, although the drug was originally developed as a radioprotectant. Phase I clinical trials suggest that amifostine may be administered in much lower doses for radioprotection than those required for protection from platinum-induced nephrotoxicity. Amifostine pharmacokinetics support this finding; elimination of the drug may be dose dependent with clearance saturated at high doses, leading to increased risk of toxicity with no added radioprotectant benefit. Large randomized trials evaluating both paclitaxel as a radiosensitizer and amifostine as a radioprotectant are needed to make any firm conclusions regarding efficacy of either drug in modulating cancer therapy.",
author = "Dorr, {Robert T}",
year = "1997",
language = "English (US)",
volume = "7",
pages = "66--76",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 2",

}

TY - JOUR

T1 - Clinical pharmacology of taxanes as radiosensitizers and the thiol- based radioprotectant amifostine

AU - Dorr, Robert T

PY - 1997

Y1 - 1997

N2 - Although many anticancer agents have been evaluated as radiosensitizing agents in cancer patients, none has demonstrated unequivocal clinical efficacy. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to enhance tumor cell response to ionizing radiation in cell culture studies. The pharmacokinetics and pharmacodynamics of paclitaxel in cancer patients receiving other highly metabolized drugs have not been well described and will be a key consideration in the development of the drug as a radiosensitizing agent. In addition, drug interaction studies demonstrate that administration sequence of paclitaxel with other chemotherapeutic agents, including cisplatin, doxorubicin, and cyclophosphamide, likely will affect its radiosensitizing efficacy. Other drugs that may affect paclitaxel radiosensitizing efficacy include corticosteroids and anticonvulsants; these interactions are particularly important in patients with central nervous system tumors, as is the question of whether paclitaxel can penetrate the blood-brain barrier. Overall, paclitaxel pharmacokinetics appear to favor radiosensitization, and results from an ongoing series of randomized trials should help define the drug's role in this setting. In contrast, amifostine, a sulfhydryl-containing agent, is currently being evaluated as a radioprotectant for normal tissues in patients who are receiving radiation therapy. Recent clinical trials have focused on amifostine's ability to reduce platinum-induced nephrotoxicity, although the drug was originally developed as a radioprotectant. Phase I clinical trials suggest that amifostine may be administered in much lower doses for radioprotection than those required for protection from platinum-induced nephrotoxicity. Amifostine pharmacokinetics support this finding; elimination of the drug may be dose dependent with clearance saturated at high doses, leading to increased risk of toxicity with no added radioprotectant benefit. Large randomized trials evaluating both paclitaxel as a radiosensitizer and amifostine as a radioprotectant are needed to make any firm conclusions regarding efficacy of either drug in modulating cancer therapy.

AB - Although many anticancer agents have been evaluated as radiosensitizing agents in cancer patients, none has demonstrated unequivocal clinical efficacy. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to enhance tumor cell response to ionizing radiation in cell culture studies. The pharmacokinetics and pharmacodynamics of paclitaxel in cancer patients receiving other highly metabolized drugs have not been well described and will be a key consideration in the development of the drug as a radiosensitizing agent. In addition, drug interaction studies demonstrate that administration sequence of paclitaxel with other chemotherapeutic agents, including cisplatin, doxorubicin, and cyclophosphamide, likely will affect its radiosensitizing efficacy. Other drugs that may affect paclitaxel radiosensitizing efficacy include corticosteroids and anticonvulsants; these interactions are particularly important in patients with central nervous system tumors, as is the question of whether paclitaxel can penetrate the blood-brain barrier. Overall, paclitaxel pharmacokinetics appear to favor radiosensitization, and results from an ongoing series of randomized trials should help define the drug's role in this setting. In contrast, amifostine, a sulfhydryl-containing agent, is currently being evaluated as a radioprotectant for normal tissues in patients who are receiving radiation therapy. Recent clinical trials have focused on amifostine's ability to reduce platinum-induced nephrotoxicity, although the drug was originally developed as a radioprotectant. Phase I clinical trials suggest that amifostine may be administered in much lower doses for radioprotection than those required for protection from platinum-induced nephrotoxicity. Amifostine pharmacokinetics support this finding; elimination of the drug may be dose dependent with clearance saturated at high doses, leading to increased risk of toxicity with no added radioprotectant benefit. Large randomized trials evaluating both paclitaxel as a radiosensitizer and amifostine as a radioprotectant are needed to make any firm conclusions regarding efficacy of either drug in modulating cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030793015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030793015&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 66

EP - 76

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 3 SUPPL. 2

ER -